Evidence map›Paper›PMID 33637569›Full record

ArticleOpen heart2021

Sarcomere mutation negative hypertrophic cardiomyopathy is associated with ageing and obesity.

Alejandro E de Feria, Andrew E Kott, Jason R Becker

Open access · goldAbstract read
In one paragraph

Article in Open heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Cardiac Cell Remodeling in Obesity and Diabetes.Handbook of experimental pharmacology · 2026
    Review
  2. Hypertrophic Cardiomyopathy is a Disease of Sarcomere Proteins.Methodist DeBakey cardiovascular journal · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. The weight of obesity in hypertrophic cardiomyopathy.Clinical medicine (London, England) · 2023
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Alejandro E de FeriaDivision of Cardiology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Andrew E KottSanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina, USA.
Jason R BeckerDivision of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA beckerj@pitt.edu.ORCID 0000-0002-2107-8179
University of Pennsylvania · USUniversity of Pittsburgh · US

Funding

Cell State Specific Modifiers of Pathological Cardiac RemodelingR01HL136824 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BECKER, JASON · 2017 to 2021
$2.0M
The role of Raf-MEK signaling in the pathogenesis of hypertrophic cardiomyopathyK08HL116803 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BECKER, JASON · 2013 to 2017
$668k
NHLBI NIH HHS K08 HL116803NHLBI NIH HHS R01 HL136824
6 · The paper itself

Abstract

backgroundDespite advances in our understanding of the genetic causes of hypertrophic cardiomyopathy (HCM), a large portion of this patient population do not carry sarcomere gene mutations when screened. It remains largely unknown why patients without sarcomere mutations develop asymmetric myocardial hypertrophy.

methodsWe performed a retrospective analysis of probands with HCM who underwent genetic testing to determine if clinical phenotypes were different depending on sarcomere mutation status. A medical history, three generation family history and clinical phenotyping were performed on 127 probands with HCM. Genetic screening was performed using clinically available HCM genetic testing panels.

resultsWe found that probands with HCM with pathogenic sarcomere mutations were over three times more likely to have a family history of HCM (66% vs 17%, p<0.0001) and were diagnosed with HCM at a much younger age (32 vs 51 years old, p<0.0001). In contrast, probands with HCM without sarcomere mutations were significantly more obese (body surface area p=0.003, body mass index p=0.04 adjusted for age) and were more likely to present with left ventricular outflow tract obstruction (p=0.0483).

conclusionPatients with sarcomere mutation negative HCM present at an older age and are more obese compared with patients with sarcomere mutation positive HCM. The role of ageing and obesity in asymmetric myocardial hypertrophy warrants further investigation.

Indexed as

MutationAdultAgingCardiomyopathy, HypertrophicCarrier ProteinsFemaleFollow-Up StudiesGenetic TestingHumansMagnetic Resonance Imaging, CineMaleMiddle AgedMyocardiumObesityPhenotypeRetrospective StudiesCarrier Proteinscardiomyopathiescardiomyopathygenetic diseaseshypertrophicinborn

Identifiers

PMID33637569
PMCPMC7919593
OpenAlexW3130049898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.